ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2010
Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Translational Proteomic Approach for Cholangiocarcinoma Biomarker Discovery, Validation, and Multiplex Assay Development: A Pilot Study.Molecules (Basel, Switzerland) · 2022Article
- Article
- Transcriptomic Analysis of the Mechanisms for Alleviating Psoriatic Dermatitis Using Taodan Granules in an Imiquimod-Induced Psoriasis-like Mouse Model.Frontiers in pharmacology · 2021Article
- Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker.Journal of translational medicine · 2020Article
- Loss of ALDH1L1 folate enzyme confers a selective metabolic advantage for tumor progression.Chemico-biological interactions · 2019Review
- Periostin promotes malignant potential by induction of epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.Hepatology communications · 2017Article
- The myofibroblast, a key cell in normal and pathological tissue repair.Cellular and molecular life sciences : CMLS · 2016Review
- An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.International journal of genomics · 2015Review
- Human liver myofibroblasts during development and diseases with a focus on portal (myo)fibroblasts.Frontiers in physiology · 2015Review
- Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.Experimental and molecular pathology · 2014Review
- Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.Molecular & cellular proteomics : MCP · 2014Article
- Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.Journal of hepato-biliary-pancreatic sciences · 2014Review
- Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.The American journal of pathology · 2012Review
- The myofibroblast, multiple origins for major roles in normal and pathological tissue repair.Fibrogenesis & tissue repair · 2012Article
- The role of the myofibroblast in tumor stroma remodeling.Cell adhesion & migrationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma is an adenocarcinoma of the liver which has increased in incidence over the last thirty years to reach similar levels to other liver cancers. Diagnosis of this disease is usually late and prognosis is poor, therefore it is of great importance to identify novel candidate markers and potential early indicators of this disease as well as molecules that may be potential therapeutic targets. We have used a proteomic approach to identify differentially expressed proteins in peripheral cholangiocarcinoma cases and compared expression with paired non-tumoral liver tissue from the same patients. Two-dimensional fluorescence difference gel electrophoresis after labeling of the proteins with cyanines 3 and 5 was used to identify differentially expressed proteins. Overall, of the approximately 2,400 protein spots visualised in each gel, 172 protein spots showed significant differences in expression level between tumoral and non-tumoral tissue with p < 0.01. Of these, 100 spots corresponding to 138 different proteins were identified by mass spectrometry: 70 proteins were over-expressed whereas 68 proteins were under-expressed in tumoral samples compared to non-tumoral samples. Among the over-expressed proteins, immunohistochemistry studies confirmed an increased expression of 14-3-3 protein in tumoral cells while α-smooth muscle actin and periostin were shown to be overexpressed in the stromal myofibroblasts surrounding tumoral cells. α-Smooth muscle actin is a marker of myofibroblast differentiation and has been found to be a prognostic indicator in colon cancer while periostin may also have a role in cell adhesion, proliferation and migration and has been identified in other cancers. This underlines the role of stromal components in cancer progression and their interest for developing new diagnostic or therapeutic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.